FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to the field of biotechnology and discloses a group of humanised recombinant antibodies, which specifically bind with human CDCP1. The claimed invention also discloses a nucleic acid, which codes an antibody, an expression vector, which contains the claimed nucleic acid and a prokaryotic or eukaryotic host cell, intended for obtaining the claimed antibodies. The method of obtaining the claimed antibodies with the application of the claimed host cell is described. A pharmaceutical composition for cancer treatment, characterised by the super-expression of CDCP1, is obtained by the application of the said antibody as the active one.
EFFECT: claimed invention makes it possible to obtain the humanised antibodies with improved CDCP1 binding properties.
20 cl, 5 dwg, 4 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH CAPABILITY OF SPECIFICALLY BINDING TO CD40 AND FAP | 2018 |
|
RU2766234C2 |
| BISPECIFIC ANTIGEN-BINDING PROTEINS | 2010 |
|
RU2573914C2 |
| COMBINATION THERAPY OF AFUCOSYLATED CD20 ANTIBODY WITH CD79b ANTIBODY-DRUGS CONJUGATE | 2014 |
|
RU2670971C9 |
| TRI- OR TETRASPECIFIC ANTIBODIES | 2010 |
|
RU2570633C2 |
| ANTIBODIES TO HER3 AND APPLICATION THEREOF | 2010 |
|
RU2560583C2 |
| HUMANIZED ANTIBODY TO BETA AMYLOID | 2013 |
|
RU2668161C2 |
| COMBINED THERAPY BASED ON TUMOUR-TARGETED IMMUNOCYTOKINES CONTAINING VARIANT IL-2, AND ANTIBODIES TO HUMAN PD-L1 | 2015 |
|
RU2710354C2 |
| COMPOSITION COMPRISING TWO ANTIBODIES ENGINEERED TO HAVE REDUCED AND INCREASED EFFECTOR FUNCTION | 2013 |
|
RU2650788C2 |
| HUMANISED ANTIBODY | 2008 |
|
RU2538709C2 |
| ANTIBODIES TO ALPHA-SYNUCLEIN AND METHODS OF USING | 2014 |
|
RU2697098C1 |
